Valuation: Acrux Limited

Market Cap 5.6M 3.94M 3.46M 3.25M 2.98M 5.56M 378M 39.07M 15.15M 193M 14.81M 14.48M 624M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 6.41M 4.52M 3.97M 3.72M 3.41M 6.37M 432M 44.75M 17.35M 221M 16.96M 16.58M 715M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
95.37%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Acrux Limited

1 day+5.56%
1 week-5.00%
Current month-9.52%
1 month-5.00%
3 months-32.14%
6 months-13.64%
Current year-36.67%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.38
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%-5.00%-36.67%-76.25% 3.77M
+1.01%+1.63%+13.44%+64.70% 46.34B
-1.02%-2.67%+38.33%+108.43% 37.12B
+0.67%+6.47%+12.98%+96.46% 12.13B
-0.08%+2.37%-10.32%+16.62% 11.7B
+0.19%0.00%+19.82%+140.74% 8.99B
+0.56%+0.08%+26.32%+37.72% 7.25B
+0.55%+4.36%+22.66%+208.30% 7.27B
-0.06%+1.51%+38.94%-16.76% 7.13B
-0.64%+4.66%-40.29%+10.76% 5.16B
Average +0.67%+1.49%+8.52%+59.07% 14.31B
Weighted average by Cap. +0.16%+0.75%+18.77%+79.50%

Financials

2025 2026
Net sales 4.49M 3.16M 2.77M 2.61M 2.38M 4.45M 302M 31.3M 12.14M 155M 11.86M 11.6M 500M 6.58M 4.63M 4.07M 3.82M 3.5M 6.53M 443M 45.9M 17.8M 227M 17.4M 17.01M 733M
Net income -5.94M -4.18M -3.68M -3.45M -3.16M -5.9M -401M -41.47M -16.08M -205M -15.71M -15.37M -662M -604K -425K -373K -351K -321K -599K -40.7M -4.21M -1.63M -20.82M -1.6M -1.56M -67.3M
Net Debt 2.77M 1.95M 1.71M 1.61M 1.47M 2.75M 187M 19.34M 7.5M 95.55M 7.33M 7.17M 309M 813K 572K 503K 472K 432K 807K 54.79M 5.67M 2.2M 28.02M 2.15M 2.1M 90.58M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
23/09/26 A$0.009500 +5.56% 65,000
21/09/26 A$0.009000 -10.00% 463,702
18/09/26 A$0.0100 0.00% 1,073,371
17/09/26 A$0.0100 0.00% 492,116
16/09/26 A$0.0100 0.00% 1,000,000

Annual profits - Rate of surprise